MedTrace Logo

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT00709878 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2015-03-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).

Conditions

  • Skin Rash

Interventions

PROCEDURE

Skin Biopsy of Skin Rash Secondary to EGFRI Use

Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.

Sponsors & Collaborators

Principal Investigators

  • Mario Lacouture, MD · Northwestern University, Department of Dermatology

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00709878 on ClinicalTrials.gov